Vancouver, British Columbia--(Newsfile Corp. - September 14, 2022) - EGF Theramed Health Corp. (CSE: TMED) (OTC Pink: EVAHF) (FSE: AUHP) (the "Company" of "EGF") has secured a term sheet agreement with Reef Capital, pursuant to which the lender will loan up to $10-million to EGF Theramed in ten tranches of $500,000.00 each. The Company may use any and all proceeds raised pursuant to the issuance of the Notes for acquisitions, working capital, and general corporate purposes, as determined by the Company's Board of Directors and its senior executive management team.

Simple interest shall accrue on the outstanding Principal Amount at a rate of 12% per annum, calculated on the basis of a 365-day year for the actual number of days elapsed (the "Interest," and together with the Principal Amount, the "Note Indebtedness"), which the Interest will be payable monthly in cash or common shares of the Company, unless converted in accordance with the terms hereof.

Upon the occurrence of certain events of default, or a change of control, the convertible debentures may at the discretion of the lender call for payment immediately of Principal and Interest outstanding at 125%.

The Company will pay for all of the Investor's due diligence and legal fees in relation to the transactions proposed in this Term Sheet, with an initial deposit of $50,000 and any remaining balance deducted from the gross proceeds from the Transaction, subject to an overall cap of $60,000 upon closing of the first tranche.

"The cannabis and psychedelic opportunities for well-funded experienced management groups are more advantageous than ever," states Connor Yuen, EGF's chief executive officer. "This new capital will allow us to take a strong strategic advantage on investment opportunities in retail prospects, and other cash flow operations that have had depressed valuations over the last period."

ABOUT EGF THERAMED HEALTH CORP.

(CSE: TMED) (OTC Pink: EVAHF) (FSE: AUHP)

EGF is a consumer technology company engaged in the provision of biomedical online services for monitoring and treating common health problems. The Company, through its subsidiaries, has assets and technologies used in the extraction and purification of botanical extracts and the creation of extract formulations, as well as medical monitoring device technology. The Company is working to collaborate with other companies for medical technology, equipment protocols and laboratory SOPs.

For more information please contact:

EGF THERAMED HEALTH CORP.
Doug McFaul
Email: dmcfaul@emprisecapital.com
Telephone: (778) 331 8505
Website
CSE Micro-site:
US OTC Markets (OTCQB):
Frankfurt Borse:

CAUTIONARY LANGUAGE

All statements in this press release, other than statements of historical fact, are "forward-looking information" with respect to the Company within the meaning of applicable securities laws, including with respect to the completion of the Transaction contemplated by the Term Sheet. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company's public filings under the Company's SEDAR profile at . Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

To view the source version of this press release, please visit